[DOI] [PMC free article] [PubMed] [Google Scholar] 99.Li Y, Rosenblit PD
In December 2025, Eli Lilly announced positive topline results from TRIUMPH-4 a 68-week Phase 3 trial in adults with obesity and knee osteoarthritis in which retatrutide delivered average weight loss of up to 71.2 lbs alongside substantial reductions in osteoarthritis pain
A SURMOUNT-1 post-hoc analysis of 2,542 women, published in Obesity in 2025, found perimenopausal women on tirzepatide lost 23% of body weight against 3% on placebo, almost identical to the premenopausal result
Research-chemical vials sold as cagrilintide or retatrutide are of unverified identity and purity
Future research should concentrate on discovering optimum microbiome biomarkers for therapy selection and creating microbiome-targeted adjuvant medicines
With it came countless makeover images primarily of women and tips on how to deal with Ozempic face (shorthand for the bitter realization that a skinnier face sometimes reveals ones advancing age)